WVE Stock Forecast & Price Target

WAVE Life Sciences is financially sound with $544.6M in cash and a developmental runway into 3Q28, driven by their RNA medicines platform PRISM and multiple modalities including RNA editing and antisense silencing. Their focus on rare and prevalent diseases, such as alpha-1 antitrypsin deficiency and obesity, shows potential for scientific breakthroughs and continued growth. The company's strategic plan to remodel their Phase 2a projections and conduct follow-up discussions and literature surveys demonstrate their commitment to addressing any uncertainties and maximizing the effectiveness of their treatment options. The human genetic literature around INHBE pLOF variants also supports a cardiometabolic benefit profile beyond fat redistribution, potentially expanding their addressable market considerably. Lastly, their INHBE silencing approach has shown no adverse effects and their BELIEVE study has established the proof-of-principle for their Activin pathway inhibition and GLP-1 agonism, highlighting their promising outlook in the field of RNA medicines.

WAVE Life Sciences is a clinical-stage biotechnology company that has a strong focus on developing novel oligonucleotide therapeutics for indications with a high unmet medical need. The company has a diverse pipeline targeting rare and prevalent diseases, including obesity, AATD, DMD, and HD. However, the company's recent 1Q26 INHBE data cut and updated financial projections have raised concerns about the potential success of its key assets and lowered our price target to $15, reflecting heightened risk. Further, the recent data and updates have increased uncertainty about the primary endpoints for accelerated approval, commercial impact, and the optimal target for ALK7 in obesity, leading us to have a negative outlook on WAVE's stock.